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GUEST EDITORIAL
Needs to Prepare for “Post-COVID-19 Syndrome”
Robert L. Klitzman
Columbia University
While attention has focused in many states and coun-
tries on the initial acute phase of the COVID-19 pan-
demic and on lowering rates of infection and deaths,
evidence suggests that among many survivors, the
virus is causing ongoing symptoms that need to be
more fully anticipated and addressed. Governments,
healthcare institutions, providers, patients, family
members, the media and the public need to recognize
and plan to meet these patients’ ongoing needs.
Data collection and reporting have concentrated on
the numbers of individuals tested, infected, hospital-
ized, admitted to intensive care units (ICUs), deceased
and recovered—on the quantity, but not the quality of
survival. Major questions are thus arising regarding
COVID-19-infected individuals who have not yet
died, but have ongoing moderate to severe symptoms.
The number of such COVID-19 patients in the U.S.
and abroad who will require ongoing care and rehabili-
tation in facilities or at home remains unknown but,
evidence suggests, it may be enormous. As of October
9 2020, around 37 million people have been infected
worldwide, with around 1.06 million dying, and
around 26 million recovering, leaving around 28%
unaccounted for (Johns Hopkins Coronavirus
Resource Center 2020). In the U.S, about 7.6 million
have been infected, around 213,000 have died and 3
million have recovered, leaving 42% unaccounted for.
Some of those unaccounted for may simply be lost to
follow up, but many are no doubt still symptomatic—
alive, but not yet recovered. In the U.S., for instance,
COVID-19 could eventually infect as many as 50% of
the population, with 5% (8.25 million) needing ICU
beds, of whom perhaps almost roughly half may die,
leaving around 4 million survivors, who may have sig-
nificant longer-term medical problems, requiring
ongoing treatment (Palosky 2020).
The proportion of hospitalized COVID-19 patients
needing ICUs or similar units has ranged across hos-
pitals in different cities and regions. At one major
U.S. hospital system, for example, 22% of hospitalized
COVID-19 patients required critical care, with 79%
requiring ventilators, and 37% remaining hospitalized
for a mean of 33 days (Cummings et al. 2020).
Yet concerns emerge regarding COVID-19 patients
who have survived ICUs and, evidence suggests, will
frequently encounter significant medical sequelae.
Among U.S. COVID-19 patients on ventilators, 31%
have needed renal replacement therapy (Cummings
et al. 2020), and 36% have developed neurological
problems, with about 6% suffering strokes or cerebral
hemorrhages (Mao et al. 2020). Post-ICU Syndrome
has also been well-described regarding other disorders,
with up to 33% and 43% of patients, respectively,
developing PTSD and depression (Jensen et al. 2015).
Most COVID-19 patients on ventilators develop
conditions suggesting acute respiratory distress syn-
drome (ARDS). But neurocognitive deficits have been
found in 73% of ARDs survivors, in general, at hos-
pital discharge, and 47% two years later (Hopkins
et al. 2005). Two years post-discharge, 23% each had
moderate to severe depression and anxiety. At one
year, 50% of former patients were unable to work,
with many requiring care from families, who must
then reduce work hours or stop employment
altogether (Griffiths et al. 2013). Many COVID-19
patients with medical sequalae have prior medical
conditions and psychosocial vulnerabilities, exacerbat-
ing these challenges.
Hospitals may want to transfer COVID-19 patients
who survive ICUs and require ongoing care to other
facilities (e.g., longer-term rehabilitation or acute care
centers) that, however, have limited capacity and may
be wary of accepting COVID-19 patients. The U.S.
has only around 38,000 rehab beds, most of which
were filled on the eve of the pandemic (Medicare
Payment Advisory Commission 2015). COVID-19
patients themselves may also fear transfer to nursing
homes and rehabs, given possible risks of infection
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there with the virus. Many patients can potentially
receive outpatient treatment and home rehab, but
social distancing can hamper home health aides and
agencies, family and friends from coming to help.
Some COVID-19 patients fear returning home,
concerned that they may still be infectious and expose
families, who may lack sufficient personal protect-
ive equipment.
In the U.S., Medicare and private insurers have fre-
quently agreed to cover physical and occupational
therapy through telehealth during the pandemic,
which can help; but hospitals then have to figure out
how to best set up such services. How long these
insurers will continue to cover such costs in the U.S.
and elsewhere, especially after the acute phase of pan-
demic ends, is also unclear.
Better-resourced hospitals have been able to afford
to transform regular wards into COVID-19 rehab or
step-down units, but doing so is not sustainable long-
term, since patients with serious diseases other than
COVID-19 will also need hospitalization. Moreover,
not all hospitals have sufficient equipment or staff to
meet such COVID-19 patients’ longer-term needs.
A recent study of patients in Italy hospitalized for
COVID-19, 5% of whom had received invasive venti-
lation, found that, an average of 60 days after onset of
symptoms, 87.4% still had virus-related symptoms,
with 55% having three or more symptoms, especially
fatigue, dyspnea and joint and chest pain (Carfi
et al. 2020).
Policymakers, public health departments, healthcare
institutions, providers, insurers, patients and families
should prepare to meet these needs. COVID-19
requires consideration of not only short-term risks
and benefits, but longer-term ones as well. Moreover,
the burdens of these longer-term problems will likely
fall disproportionately on vulnerable populations—the
poor, the elderly, and persons of color. Governments
should thus begin collecting data on the nature and
extent of these longer-term problems, including spe-
cific kinds of national, state and local hospital, out-
patient and home services required, and how best to
meet these. Policy makers should also allocate suffi-
cient resources to meet these growing needs for out-
patient services.
In the U.S. and elsewhere, funds available thus far
may be insufficient. Up to about 2 million hospital-
ized U.S. COVID-19 patients will have no insurance,
and this number is increasing due to job losses caused
by the pandemic. Undocumented immigrants are also
disappropriately represented among COVID-19
patients, posing challenges for rehab centers and
insurers. Among the approximately 10 million
undocumented immigrants in the U.S., around 65%
are Latino, who as a group, have been more likely
than Caucasians, for instance, to become infected and
die of COVID-19 (Oppel et al. 2020). Hospitalization
of uninsured COVID-19 patients may ultimately cost
$13.9–$41.8 billion—up to 40% of the amount
Congress established to assist healthcare institutions’
responses to the pandemic (Palosky 2020).
Given the many uncertainties and unknowns
regarding the virus and its clinical effects, a robust
research agenda is essential, including longitudinal
studies over several years to understand the specific
nature of post-COVID-19 symptoms, how best to pre-
vent, minimize, and treat these, what services and care
are most effective, which patients are at highest risk—
how age, prior co-morbidities, sociodemographic, and
other factors influence the prevalence and outcomes—
and what specific obstacles emerge.
Appropriate public health messaging is also crucial
to enhance education of patients and the public-
at-large to set appropriate expectations about the
challenges survivors may encounter. The fact that
COVID-19 survivors may suffer long-term difficulties
can, however, potentially further motivate people to
protect themselves.
While attention has understandably thus far focused
on the initial, acute stages of the COVID-19 pandemic,
we must now attend, too, to these mounting longer-
term medical and psychosocial sequelae of infection–-
what I term “Post-COVID-19 Syndrome”—and how
best to meet this growing challenge.
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